Nucleai
Latest round
- Series B
Last raised
- Apr 2024
Total raised
- $59M
Investors
- 7
About Nucleai
Based in Tel Aviv, Israel, and founded in 2018 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai Inc. operates as a developer of artificial intelligence-based software solutions that use machine learning algorithms to detect cancer and gastrointestinal diseases in humans. In April 2024, Nucleai Inc. Nucleai focuses on AI-driven spatial biology technology to enhance precision medicine, improve drug development, and aid clinical treatment decisions. Their platform uses advanced geospatial AI methods to analyze cellular interactions in biopsies, translating data into actionable insights. This technology supports pharmaceutical companies in drug development and biomarker discovery, aiming to optimize therapeutic strategies and patient outcomes.
Who invested in Nucleai
7 investors across 4 rounds
See all investors in Nucleai
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nucleai
Who invested in Nucleai?
Nucleai has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nucleai raised?
Nucleai has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Nucleai last raise money?
Nucleai's most recent round on record is a Series B, in Apr 2024.
What does Nucleai do?
Based in Tel Aviv, Israel, and founded in 2018 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai Inc.
Where is Nucleai headquartered?
Nucleai is headquartered in Tel Aviv, Israel.
Which VCs invest in companies like Nucleai?
Among active investors with capital left to deploy, Yufu Capital, ICBC Capital Management, Ningbo Tongshang Fund and Boc Private Equity Firm back software companies at Nucleai's stage. Their profiles are linked below.
VCs backing software startups at Series B
Raising like Nucleai? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.